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Abstract19
Real-time quantitative PCR (qPCR) is invaluable for investigating changes in gene expression20
during early development, since it can be performed on the limited quantities of mRNA 21
contained in individual embryos. However, the reliability of this method depends on the use 22
of validated stably expressed “reference genes” for accurate data normalization. The aim of 23
this study was to identify and validate a set of reference genes suitable for studying gene 24
expression during equine embryo development. The stable expression of 4 carefully selected 25
reference genes and 1 developmentally regulated gene was examined by qPCR in equine26
morula to expanded blastocyst stage in vivo embryos. SRP14, RPL4 and PGK1 were 27
identified by geNorm analysis as stably expressed reference genes suitable for data 28
normalization. RPL13A expression was less stable and changed significantly during the period 29
of development examined, rendering it unsuitable as a reference gene. As anticipated, CDX230
expression increased significantly during embryo development supporting its possible role in 31
trophectoderm specification in the horse. In summary, we demonstrated that evidence-based32
selection of potential reference genes can reduce the number needed to validate stable 33
expression in an experimental system; this is particularly useful when dealing with tissues that 34
yield small amounts of mRNA. SRP14, RPL4 and PGK1 are stable reference genes suitable35
for normalizing expression for genes of interest during in vivo morula to expanded blastocyst 36
development of horse embryos.37
38
Introduction39
In eutherian mammals, pre-implantation embryo development is a period of dynamic 40
transition, spanning a range of important events that include cell cleavage, embryonic genome 41
activation, cell lineage segregation, blastocyst formation, initial interaction with the 42
endometrium and ultimately implantation. Large fluctuations in the transcriptome occur 43
during this period, as a result of the switch from maternally-produced to embryo-produced 44
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mRNA transcripts and an increase in the expression of growth, differentiation and 45
transcription factors (Telford et al. 1990; Hamatani et al. 2004). Examining the expression of 46
genes involved in these critical developmental processes is a more sensitive way of assessing47
the health and normal development of embryos than morphological criteria alone. This 48
understanding may be invaluable for identifying causes of early embryonic loss, and in 49
assisting the development of safe and effective in vitro assisted reproductive technologies.50
51
In the horse, the embryonic genome becomes transcriptionally active by the third cleavage52
stage (5 to 8 cells) at approximately 72 h after fertilization (Brinsko et al. 1995; Grondahl and 53
Hyttel 1996). However, the early horse embryo remains for an unusually long period 54
(approximately 6 days) in the oviduct, making access to in vivo cleavage stages impossible 55
without invasive surgery or slaughter (Betteridge 2007). When the embryo finally enters the 56
uterus on day 6–6.5 it is usually at the compacted morula stage with a thick zona pellucida,57
but develops into an early blastocyst with the first visible signs of trophectoderm versus inner 58
cell mass (ICM) differentiation within a few hours (Battut et al. 1997; Betteridge 2007).59
During initial intra-uterine development, the zona pellucida thins before being shed to leave60
an expanded blastocyst at around day 7–8 that is completely surrounded by a unique 61
glycoprotein tertiary embryo coat, the blastocyst ‘capsule’, that had formed between the 62
trophectoderm and the zona pellucida (Tremoleda et al. 2003; Stout et al. 2005). The capsule63
remains until approximately day 21 of gestation and appears to be essential for the 64
establishment and maintenance of pregnancy (Betteridge et al. 1982; Stout et al. 2005).65
66
Morula to expanded blastocyst stage equine embryos are of practical interest because these 67
stages are used commercially for embryo transfer and cryopreservation; and are the stages to 68
which in vitro produced or cloned embryos are cultured prior to transfer to the uterus of a69
mare (Stout 2006). In addition, these are the earliest in vivo developmental stages that can be 70
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obtained without surgical intervention. The morula to blastocyst transition also spans71
important developmental events including: (i) the first (ICM vs. trophectoderm) and second 72
(epiblast vs. hypoblast) cell lineage segregation events (Ralston and Rossant 2005; Kuijk et 73
al. 2008; Harvey et al. 2009); (ii) formation of the blastocyst capsule (Stout et al. 2005); and 74
(iii) rapid embryonic expansion and an increase in cell number from around 160 to over 2,90075
(Tremoleda et al. 2003; Rambags et al. 2005). Moreover, this is a critical period for assisted 76
reproductive technologies in the horse because: (i) embryonic stem cells are usually isolated 77
from the ICM (Saito et al. 2002; Li et al. 2006); (ii) embryos >300 µm show much poorer 78
survival following cryopreservation than smaller embryos (Slade et al. 1985; Tharasanit et al.79
2005); and (iii) capsule formation is abnormal in in vitro produced embryos (Tremoleda et al.80
2003). Furthermore, early embryonic death during the first 2 to 5 weeks after fertilization is a 81
source of considerable economic loss to the equine breeding industry, and is particularly 82
prevalent in aged mares (Ball 1988; Morris and Allen 2002). Aged mares are often desirable83
for breeding stock because they have either competed with distinction or produced earlier 84
offspring that have proven to be gifted athletes. Thus, there are both strong economic and 85
research justifications for examining this particular window of early embryonic development 86
in the horse.87
88
To examine the dynamics of gene expression during early embryo development, one must 89
obtain sufficient quantities of mRNA transcripts for analysis. Real-time quantitative 90
polymerase chain reaction (qPCR) analysis is fast, reliable, and sufficiently sensitive to 91
provide accurate relative quantification of gene expression in small quantities of tissue such as 92
single embryos (Bustin 2002). However, because of its sensitivity qPCR can lead to 93
misinterpretation if proper standardization is not used. Unwanted variation can arise from 94
differences in the amount of tissue used, in the total amount of mRNA in different cells and at 95
different times, and from variation in mRNA extraction, cDNA synthesis by reverse 96
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transcriptase and PCR amplification efficiencies (Vandesompele et al. 2002). The use of 97
internally expressed reference genes is one of the most widely adopted methods of 98
compensating for this unwanted variation in qPCR experiments (Vandesompele et al. 2002).99
A good reference gene should be stably expressed across the tissue and treatments of interest,100
with <2-fold maximum change between samples (de Jonge et al. 2007). No universal 101
reference gene exists. Thus a number of studies have demonstrated the need to accurately 102
validate the stability of reference genes in the system under investigation and, once validated, 103
to use multiple reference genes to accurately normalize gene expression data (Thellin et al.104
1999; Vandesompele et al. 2002; Dheda et al. 2005).105
106
To date, reliable reference genes have not been described for early pre-implantation embryo 107
development in the horse. Indeed, published papers have mostly used a single non-validated 108
reference gene to normalize gene expression data in early horse embryos. One obstacle to 109
validation is that collecting large numbers of in vivo horse embryos is time consuming and 110
expensive, primarily because superovulation regimens are relatively ineffective (Allen 2005). 111
Since embryos are limited and each embryo contains minimal amounts of mRNA (which is 112
also required to investigate the expression of genes of biological interest), we questioned the 113
practicality of testing a large array of historically common reference genes to identify the best114
3 or 4 for normalization, as has been reported previously for early pre-implantation embryos 115
of other species (Goossens et al. 2005; Kuijk et al. 2007; Mamo et al. 2007; 2008). Instead, 116
we chose to evaluate a small number of reference genes previously indentified as being stably 117
expressed in developing embryos of other species (Kuijk et al. 2007) or across a diverse range118
of tissues (de Jonge et al. 2007). A parallel reference gene study was recently reported (Smits 119
et al. 2009) but was restricted to blastocysts derived under various conditions or subjected to 120
cryopreservation (in vivo versus in vitro versus in vitro cryopreserved), after the RNA had 121
been subjected to global amplification; these reference genes may not be suitable for122
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comparing early equine embryos across different stages of development or for embryos not 123
subjected to prior RNA amplification. Here we demonstrate that using an evidence-based 124
minimalist strategy, we were able to identify stably expressed reference genes suitable as125
normalization factors for morula to expanded blastocyst stage equine embryos.126
127
Materials and methods128
Collection of in vivo embryos129
Twenty one embryos were recovered 6.5–7 days after ovulation from 16 Dutch Warmblood 130
mares (aged 4–12 years) inseminated with semen from a single fertile stallion as described 131
previously (Rambags et al. 2008). Embryos were recovered by non-surgical uterine lavage 132
using 3 x 1 L pre-warmed (37°C) lactated Ringer’s solution (LRS; Baxter, Lessines, Belgium) 133
supplemented with 0.5% fetal calf serum (FCS; Greiner Bio-One, Alphen aan den Rijn, 134
Netherlands). Embryos were then ‘washed’ through 10 wells of LRS to remove any maternal 135
cells or residual FCS. Embryo diameter was measured using an eye-piece micrometer 136
attached to a SZ60 dissecting microscope (Olympus, Zoeterwoude, Netherlands) and embryos 137
were further classified by developmental stage (morula, early blastocyst or expanded 138
blastocyst; Fig. 1) and quality grade (1–4) as described by Tremoleda et al. (2003). Embryos 139
were snap-frozen in liquid nitrogen in 10 µl LRS and stored at –80°C until RNA extraction. 140
All animal procedures were approved by Utrecht University’s Animal Experimentation 141
Commission (DEC).142
143
RNA extraction and cDNA synthesis144
Total RNA was extracted from whole individual embryos in 600 µl buffer RLT using an 145
AllPrep DNA/RNA/Protein Mini Kit, and subjected to on-column DNase I digestion using an 146
RNase-Free DNase Set (both Qiagen, Venlo, Netherlands) according to the manufacturer’s 147
instructions. RNA was eluted in a final volume of 35 µl RNase-free water. Since the amount 148
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of RNA recovered from individual embryos in preliminary trials was below the detection 149
limit of a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), all 150
of the RNA from each individual embryo was synthesized into cDNA. +RT samples were 151
synthesized in a 40 µl reaction volume that contained 24 µl embryo RNA, 1x First strand 152
buffer, 5 mM DTT, 0.5 mM dNTPs (Promega, Madison, WI, USA), 600 ng random primers, 153
40 U RNase In (Promega) and 200 U Superscript III reverse transcriptase (all Invitrogen, 154
Breda, Netherlands unless otherwise stated). To test for genomic DNA (gDNA) 155
contamination, –RT samples were made up in a 20 µl reaction volume that contained 8 µl 156
embryo RNA and the same reagent concentrations but without reverse transcriptase. RNA 157
was added to the reaction mixture after an initial denaturation step of 5 min at 70°C followed 158
by 1 min on ice. Thereafter, the reaction was incubated for 5 min at 25°C, 1 h at 50°C and 5 159
min at 80°C. The quality and purity of cDNA from each embryo was verified using 160
conventional PCR and generic actin-family primers (that amplify both cDNA and any 161
contaminating gDNA of β-actin, γ1-actin and a hypothetical mRNA product identified in the 162
NCBI horse genome database; Table 1). For the PCR, the total reaction volume was 25 µl 163
containing 1 µl +RT or –RT embryo cDNA, 1x PCR buffer, 2 mM MgCl2, 0.2 mM dNTPs 164
(Promega), 0.5 µM forward primer, 0.5 µM reverse primer and 0.625 U HotStarTaq DNA 165
polymerase (all Qiagen unless otherwise stated). PCR cycling conditions consisted of 15 min 166
at 95°C followed by 35 cycles of 30 sec at 94°C, 30 sec at primer-specific annealing 167
temperature (see ACT Table 1) and 1 min at 72°C; with a final extension of 10 min at 72°C. 168
Products were visualized on 1% agarose gels. If suitable for PCR amplification and free of 169
gDNA contamination, both +RT and –RT embryo cDNA samples were diluted 10-fold and 170
frozen at –20°C in multiple single-reaction aliquots until required for qPCR analysis.171
172
Reference gene selection and primer design173
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In this study, we tested the expression of four potential reference genes, Phosphoglycerate 174
kinase 1 (PGK1), Signal recognition particle 14kDa (SRP14), and ribosomal proteins L4 175
(RPL4) and L13A (RPL13A). PGK1 was ranked among the 3 most stably expressed genes in 176
oocytes and throughout pre-implantation embryo development in the pig (Kuijk et al. 2007).177
SRP14, RPL4 and RPL13A were ranked among the top 15 most stably expressed genes out of 178
13,037 unique genes tested across 13,629 different human and 2,543 different mouse gene 179
array samples, derived from a wide variety of different tissues and experimental conditions 180
(de Jonge et al. 2007). Most of these top 15 genes were ribosomal and their stability differed 181
according to species (de Jonge et al. 2007). Thus, both RPL4 and RPL13A (ranked 2nd and 4th182
in mouse but 12th and 5th in man respectively) were tested to evaluate which was most stably 183
expressed in horse tissue. In addition, Caudal type homeobox 2 (CDX2), was included in the 184
study as a biologically variable ‘control’ gene. CDX2 is a developmentally regulated 185
transcription factor known to specify trophectoderm during the period of blastocyst formation 186
in the mouse (Strumpf et al. 2005). Inclusion of CDX2 permitted comparison of stability 187
between a developmentally regulated gene and candidate reference genes, and provided a 188
target gene to better assess the effects of normalization. Moreover, this enabled us to189
characterize the pattern of CDX2 expression in the developing horse blastocyst since this was 190
not yet known. Equine-specific CDX2 qPCR primers were obtained from published sequences 191
(de Mestre et al. 2009); for the remaining genes, human and mouse mRNA sequences were 192
used to BLAST the NCBI horse genome (NCBI Horse Genome Resources) to identify 193
homologous equine mRNA and gDNA sequences. These were then imported into PerlPrimer 194
v1.1.17 (Marshall 2004) to design intron spanning/intron-exon overlapping mRNA-specific 195
primers suitable for qPCR. The sequence-specificity of primers was confirmed by BLAST 196
analysis against the NCBI horse genome (Table 1).197
198
Primer validation and quantitative PCR199
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Primers for each gene were optimized and tested for specificity using 10 µl of 100-fold 200
diluted positive control small intestine (for CDX2) or testis cDNA. Optimal annealing 201
temperatures (TA) were determined by temperature gradients that spanned the primer melting 202
temperature (Tm) ±5°C. The optimal TA for each primer pair gave the highest quantity and 203
purity of PCR product based on the height, and clean single peak, of its melt curve coupled 204
with an early Cq score during qPCR (Table 1). Once optimized, qPCR product from each 205
primer pair was run with a 100 bp DNA ladder (Invitrogen) on a 2% agarose electrophoresis 206
gel and its size was verified using Quantity One v4.3 software (BioRad, Hercules, CA, USA) 207
(Fig. 2). Products were also sequenced using their respective forward and reverse primers in 208
separate sequencing reactions with an ABI PRISM BigDye Terminator v3.1 Ready Reaction 209
Cycle Sequencing Kit and an ABI PRISM 3130xl DNA sequencer (both Applied Biosystems, 210
Nieuwerkerk aan den IJssel, Netherlands). Specificity was validated by comparing these 211
sequences with those from the NCBI horse genomic database. Once validated, qPCR products 212
were precipitation-purified and the absolute amount of DNA quantified by Nanodrop 213
spectrophotometer (Nanodrop Technologies), before 5-fold serial dilution in 10 mM Tris-Cl 214
(pH 8.5) to yield 8 different standard solutions ranging from 100 fg to 1.28 ag. Standards 215
were tested in duplicate and the equivalent of 10 µl of 10-, 100- or 500-fold diluted cDNA 216
from each of 3 test embryos was included on the plate to determine if amounts of cDNA from 217
individual embryos could be quantified within the range of the standard curves.218
219
Quantitative PCR was performed to optimize all primers and standards and to run final 220
embryo plates using an iQ5 Real Time PCR Detection System and iQ5 Optical System 221
Software v2.0 (BioRad). The total reaction volume was 25 µl per well containing 1x iQ 222
SYBR Green Supermix (BioRad), 0.5 µM forward primer and 0.5 µM reverse primer 223
(Ocimum Biosolutions, IJsselstein, Netherlands) and, for final embryo plates, one of each of 224
the following samples in separate reactions: (i) 100 fg–6.4 ag of 5-fold diluted standards 225
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(n=7); (ii) 10 µl of 10-fold diluted embryo cDNA (n=21); (iii) 10 µl of 10-fold diluted embryo 226
–RT sample (n=21); or (iv) 10 µl DNase/RNase-free water (Invitrogen) as no-template 227
control. All samples except the –RT, were run in duplicate (technical replicates), with 228
embryos also divided into biological replicates consisting of 5 morulae, 7 early and 9 229
expanded blastocysts. Both frozen-validated and freshly-prepared standards were included in 230
duplicate on each plate. Due to space limitations, –RT samples were run on a separate plate in 231
a subsequent run on the same day using identical standards. PCR cycling conditions consisted 232
of 4.5 min at 95°C followed by 40 cycles of 15 sec at 95°C, 30 sec at optimal TA and 30 sec at 233
72°C during which fluorescence was acquired; followed by a melt-curve protocol that 234
consisted of 1 min at 95°C, 1 min at optimal TA, then 10 sec at optimal TA increasing to 95°C 235
by 0.5°C per cycle during which a second round of fluorescence was acquired. Baseline and 236
threshold (~100 relative fluorescence units; RFU) values were manually adjusted and samples 237
with non-uniform/failed amplification, primer dimers, or with amplified products in the 238
corresponding –RT sample were excluded from further analysis for all genes.239
240
Reference gene stability and gene expression normalization241
geNorm v3.5 software was used to compare the stable expression of each reference gene over 242
the different embryonic development stages as described by Vandesompele et al. (2002). 243
Raw, non-normalized data obtained during qPCR detection was exported from the iQ5 244
software as starting quantities, derived from the standard curve. Relative starting quantities, in 245
which the highest value was set to 1 for each gene, were then calculated and this data was 246
imported into geNorm for analysis. The gene expression stability measure (M) and pair-wise 247
variation (V) for a particular gene compared with all other tested reference genes was 248
calculated as previously described (Vandesompele et al. 2002). The optimum number of 249
reference genes to use for normalization was achieved when V≤0.15; a limit beyond which 250
inclusion of further less-stable reference genes for normalization is considered unwarranted 251
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(Vandesompele et al. 2002). The relative expression of all 5 genes among embryos was 252
normalized against the top 3 reference genes using normalization factors obtained by 253
calculating their geometric mean from standard curve derived starting quantities.254
255
Statistical analysis256
Data were analyzed using SYSTAT 10.2 (Systat Software, Chicago, IL, USA) and assessed 257
for normal distribution, equal variance between groups, and the presence of outliers (Quinn 258
and Keough 2002). Relationships were tested by pair-wise Pearson's correlation with a post-259
hoc Bonferroni test. Differences in average gene expression between stages of embryo 260
development were tested by unbalanced ANOVA with a post-hoc pair-wise Bonferroni test. 261
Probabilities (P) ≤0.05 were considered to be significant.262
263
Results264
Embryo collection and sample quality265
Twenty one grade 1–2 embryos were collected; they consisted of 5 morulae, 7 early and 9 266
expanded blastocysts ranging in diameter from 126–138, 134–196 and 230–680 µm 267
respectively (Fig. 1). Conventional PCR amplification using generic actin primers (Table 1)268
confirmed that the cDNA from all embryos was suitable for PCR amplification and was free 269
of gDNA contamination, based on the presence or absence of a product in the +RT and –RT 270
samples respectively (data not shown).271
272
Primer validation, quantitative PCR efficiency and relative gene expression273
Intron spanning/intron-exon overlapping mRNA-specific primers were designed for PGK1, 274
SRP14, RPL4, RPL13A and CDX2, and the optimal annealing temperature (TA) for each 275
primer pair gave rise to a clean single product peak/dissociation temperature during melt 276
curve analysis (Table 1). PCR products for each primer pair were of the expected size when 277
For Review Purposes Only/Aux fins d'examen seulement
12
visualized by agarose gel electrophoresis (Fig. 2) and DNA sequencing confirmed that the 278
products were specific to the target genes of interest (data not shown). Amplification was 279
robust on standards ranging from 100 fg–32 ag (and down to 6.4 ag for RPL13A and CDX2) 280
and gave amplification efficiencies of 91.4, 98.6, 102.8, 92.8 and 100.9% (R2=0.985, 0.988, 281
0.995, 0.995 and 0.993; slope=-3.547, -3.356, -3.258, -3.507, -3.300; y-intercept=29.039, 282
32.234, 26.371, 27.233, 24.922) for PGK1, SRP14, RPL4, RPL13A and CDX2 respectively.283
All 5 genes were expressed in all test embryos and the equivalent of 1 µl undiluted or 10-fold 284
diluted embryo cDNA was sufficient to amplify within the working range of the standards for 285
each gene. In the final plates, wells containing primer dimers were excluded from further 286
analysis and expression for all genes was below detectable levels in –RT samples.287
288
All 5 genes were expressed in morula to expanded blastocyst stage equine embryos and there 289
was a strong correlation between the level of expression and embryo size (relative expression 290
vs. embryo diameter R=0.92, 0.88, 0.88, 0.88 and 0.81; P<0.001 for CDX2, RPL4, RPL13A, 291
SRP14 and PGK1 respectively; Fig. 3). Pure products were amplified in all embryos; however292
one duplicate failed to amplify PGK1 in cDNA from 4 embryos (E24, E31, E16 and E17) and 293
one replicate failed to amplify CDX2 in cDNA from 2 embryos (E19 and E16). PGK1 showed294
the greatest increase in gene expression at the expanded blastocyst stage (368-fold higher) 295
relative to the smallest morula, followed by CDX2 (332-fold higher). RPL13A expression 296
changed the least (117-fold higher) during this period of development. The expression of all 297
genes increased markedly in expanded blastocysts, particularly in those with an embryo 298
diameter >400 µm (E13–E5; Fig. 3).299
300
Reference gene expression stability301
A ranking of the stable expression of each reference gene across the different developmental 302
stages, based on the gene expression stability measure (M), is shown in Table 2. RPL4 was 303
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the most stably expressed gene followed by SRP14 and RPL13A, while CDX2 showed the 304
least stable expression. To test whether RPL4 and RPL13A may be co-regulated, we examined305
whether removal of one from the analysis significantly affected the stability ranking of the 306
other. Exclusion of either of these ribosomal genes resulted in a single-rank decrease in the 307
apparent stability of the remaining gene, although expression of each was still more stable 308
than CDX2 (Table 2). These results indicate that the expression patterns of these two genes 309
are so similar that they support each others favourable ranking. Since RPL4 and RPL13A form 310
part of the same ribosomal unit in cells, these results infer that RPL4 and RPL13A may be, at 311
least partially, co-regulated and as such should not be used jointly as normalization factors.312
313
The pair-wise variation (V) was calculated for the two most stably expressed genes (from 314
each ranking in Table 2) when the next most stable genes were included successively, i.e. 315
V2/3, V3/4 and V4/5 (Fig. 4). We defined the optimal number of genes for normalization as 316
the minimum number sufficient to reduce the pair-wise variation to 0.15, as recommended by 317
Vandesompele et al. (2002). With all genes included in the analysis, the pair-wise variation of 318
RPL4, SRP14 and RPL13A (V2/3) was already below this threshold (V=0.143), decreased 319
further following the addition of PGK1 (V3/4), but increased after the addition of the least 320
stably expressed developmentally regulated gene, CDX2 (V4/5; Fig. 4a). Without RPL4, the 321
pair-wise variation of SRP14, PGK1 and RPL13A (V2/3) did not decrease below the threshold 322
(V=0.167) but did increase following the addition of CDX2 (V3/4; Fig. 4b). However, in the 323
absence of RPL13A, the pair-wise variation of SRP14, RPL4 and PGK1 (V2/3) decreased to 324
the threshold (V=0.151) but increased above this limit after the addition of CDX2 (V3/4; Fig.325
4c). These results confirm that, in early horse embryos, RPL4 is more stably expressed than326
RPL13A; as such we recommend the use of RPL4 in combination with SRP14 and PGK1 as 327
suitable reference genes for normalization purposes.328
329
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Normalized gene expression330
The relative expression levels of all 5 genes for each embryo were normalized against the 331
chosen reference genes (SRP14, RPL4 and PGK1; Fig. 5). Given its putative role in early 332
embryonic development, CDX2 was, not surprisingly, the least stably expressed gene across 333
in vivo equine embryos ranging from 126 µm morulae to 680 µm expanded blastocysts. The 334
ratio of the highest expression of this gene (in embryo E25) to the lowest was 9.8-fold, this 335
compared to 1.8 (E5), 1.8 (E4), 2.0 (E27) and 2.5-fold (E24) differences in expression for336
SRP14, RPL4, PGK1 and RPL13A respectively (Fig. 5a–e). Moreover, the overall pattern of337
CDX2 expression across individual embryos was considerably more variable than for any of 338
the potential reference genes.339
340
Normalized relative expression for all five genes was also examined in the embryos after 341
grouping by developmental stage (morula, early blastocyst and expanded blastocyst; Fig. 6).342
After grouping, PGK1 appeared the most stably expressed gene, followed by SRP14 and 343
RPL4 with less than 1.1, 1.2 and 1.2-fold difference in expression respectively between the 344
stages (Fig. 6a–c). The difference in RPL13A gene expression was over 1.5-fold and 345
decreased significantly between morula and expanded blastocyst stages, again suggesting that 346
this gene is less suitable for use as a normalization factor across these developmental stages in 347
the horse (P=0.007; Fig. 6d). Expression of CDX2 increased significantly by more than 1.8-348
fold from the morula to expanded blastocyst stage, consistent with a role in trophectoderm 349
specification (P=0.02; Fig. 6e).350
351
Discussion352
This study identified SRP14, RPL4 and PGK1 as stably expressed reference genes suitable for 353
use in normalizing expression data from morula to expanded blastocyst stage in vivo horse 354
embryos. RPL13A was found to be less suitable due to its probable co-regulation with RPL4355
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and less stable expression which changed significantly during development. CDX2 expression 356
increased during embryo development, consistent with a role in the formation of 357
trophectoderm, as described for mouse embryos. The pattern of expression described here for 358
equine embryos, suggests that the function of CDX2 is conserved between mouse and horse. 359
360
During this study, we were able to demonstrate that an evidence-based minimalist approach to 361
the selection of potential reference genes can reduce the number that need to be tested to 362
identify a pool suitable for normalization purposes; this is particularly relevant for early-stage 363
embryos or other biological materials where minimal amounts of mRNA are available. Two 364
of the 3 final reference genes (SRP14 and RPL4) tested in this study were chosen based on 365
their highly stable expression in more than 2,500 different mouse and 13,600 human gene 366
array samples (ranked 6th and 2nd in mouse, and 7th and 12th in man respectively out of 13,037 367
genes tested; de Jonge et al. 2007). RPL4 also ranked among the 2 most stably expressed368
reference genes tested across 17 different porcine tissues, and in regenerating mouse liver 369
(Nygard et al. 2007; Takagi et al. 2008); while SRP14 ranked among the 2 most stably 370
expressed genes in human myocardium (Pilbrow et al. 2008). Since care should also be taken 371
to select an array of genes that is relevant to the samples under investigation, PGK1 was also 372
selected. Previous work in our laboratory identified PGK1 as a very stably expressed gene373
during porcine pre-implantation embryo development (Kuijk et al. 2007); PGK1 also ranked 374
among the 3 most stably expressed genes in rat oligodendrocytes and differentiating mouse 375
and human embryonic stem cells (Willems et al. 2006; Nelissen et al. 2010). Moreover, the 376
stability ranking and pair-wise variation of the best 3 reference genes identified in the current 377
study were lower than the 4 best reference genes advocated in the equine expanded blastocyst 378
study reported by Smits et al. (2009), suggesting that they may be valuable additions to the 379
pool of potential reference genes for studies on early equine embryo development.380
381
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RPL4 and RPL13A are both ribosomal proteins that form part of the large 60S subunit which 382
is responsible for translational elongation (Dresios et al. 2006). Although evidence from 383
archaeal homologues suggests that they do not directly interact (Ban et al. 2000), and 384
although each has been reported to have separate and distinct extra-ribosomal functions in 385
prokaryotes and man (Warner and McIntosh 2009), it is likely these genes are co-regulated. 386
Functionally co-regulated genes can confound geNorm analysis because their pair-wise 387
variation will be smaller across experimental treatments than unrelated genes, leading to an 388
overestimate of expression stability. RPL4 and RPL13A were both included in the current389
study to determine which was more stably expressed in horse embryos, since they have been 390
shown to exhibit species-specific differences (ranked 2nd and 4th in mouse but 12th and 5th in 391
man respectively; de Jonge et al. 2007). Exclusion of one of these two ribosomal genes from 392
geNorm analysis negatively affected the stability ranking of the other (Table 2), supporting 393
the hypothesis that these genes are co-regulated and as such should not be used jointly as 394
normalization factors. In this respect, RPL13A was discounted as a reference gene because its 395
expression was less stable than RPL4, and not sufficient to reduce the pair-wise variation of 396
the 3 best reference genes below the recommended threshold (Table 2 and Fig. 4b). After 397
normalization, RPL13A gene expression was shown to decrease significantly during morula to 398
expanded blastocyst development (Fig. 6d) and, although the magnitude of this change was 399
small (just over 1.5-fold), it does suggest that RPL13A is not stably expressed under these 400
conditions, and its use as a reference gene is thus not recommended.401
402
CDX2 was included as a ‘developmentally regulated’ control in this study because it is known 403
to be highly regulated during blastocyst formation in the mouse (Strumpf et al. 2005). As 404
expected, CDX2 had the lowest stability ranking and greatest negative effect on increasing 405
pair-wise variation among the tested genes (Table 2 and Fig. 4). In addition, normalized 406
CDX2 expression was more variable across individual embryos with a nearly 10-fold 407
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difference between the highest and lowest expression (Fig. 5e). Interestingly, when embryos 408
were grouped by stage of development, CDX2 expression increased significantly nearly 2-fold 409
from the morula to the expanded blastocyst stage (Fig. 6e). This pattern is consistent with an 410
ever-increasing proportion of cells with a trophectodermal phenotype, suggesting that, as in 411
the mouse (Strumpf et al. 2005), CDX2 plays a role in trophectoderm specification in the 412
horse.413
414
Examination of gene expression in single embryos in this study permitted us to observe 415
biological variation often masked when pooled embryos are compared. The strong correlation 416
(R>0.8) observed in single embryos between relative gene expression and embryo diameter 417
for all 5 genes, coincides with a rapid increase in cell number as horse embryos develop from 418
a morula into an expanded blastocyst (from 160 to over 2,900) (Rambags et al. 2005).419
Clearly, horse embryos, even those of the same developmental stage, differ greatly from one 420
another in size and cell number. However, good normalization should be able to compensate 421
for these changes, and the combination of SRP14, RPL4 and PGK1 appears to do this 422
effectively (compare Fig. 3 and 5). Although this single sample approach has been advocated 423
previously (Jolly et al. 2005), it has not been widely used for pre-implantation embryos 424
(Mamo et al. 2007; 2008).425
426
In summary, we have validated SRP14, RPL4 and PGK1 as a suitable pool of reference genes 427
for normalizing gene expression data for morula to expanded blastocyst stage in vivo equine 428
embryos; this should assist in studies to examine expression of genes potentially involved in 429
normal or compromised development in this species. Due to its probable co-regulation with 430
RPL4 and less stable expression that changes during development, RPL13A is not advocated 431
as a reference gene in this system.432
433
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Figure Legends575
Fig. 1. Representative pictures of in vivo produced equine embryos used in this study.576
(a) morula (embryo E4) with a thick zona pellucida; (b) early blastocyst (embryo E9) with a 577
thin zona pellucida, ring of developing trophectoderm (arrow) and signs of cavitation; and (c) 578
expanded blastocyst (embryo E13) with a thin capsule (arrowhead), a large blastocoel cavity 579
and a clearly identifiable inner cell mass (arrow). zp, zona pellucida; c, cavitation; scale 580
bar=100 µm.581
582
Fig. 2. PCR product size for candidate reference genes. Products separated on a 2% 583
agarose gel in parallel with a 100 bp DNA ladder (L), were of the expected sizes (PGK1 260 584
bp; RPL4 203 bp; RPL13A 198 bp; SRP14 100 bp; CDX2 136 bp). Numbers shown indicate 585
DNA fragment size (bp) of the ladder.586
587
Fig. 3. Relative gene expression for individual equine embryos. Embryos arranged in order 588
of increasing embryo diameter (µm) and developmental stage (embryos E24–E4, morulae; 589
embryos E17–E21, early blastocysts; embryos E30–E5, expanded blastocysts). The mean and 590
range (error bars) of technical duplicates are plotted. Gene expression in the smallest embryo 591
was taken as the reference to calculate relative amounts as development progressed.592
593
Fig. 4. Determination of the optimal number of reference genes for normalization. Pair-594
wise variation (V) between two sequential normalization factors containing an increasing 595
number of less stable reference genes analysed (a) for all genes; (b) without RPL4; and (c) 596
without RPL13A. An arbitrary cut-off of V≤0.15 (dashed line) was used as a limit below597
which inclusion of further reference genes for normalization is unwarranted (Vandesompele et 598
al. 2002).599
600
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Fig. 5. Normalized gene expression in individual equine embryos. Embryos arranged in 601
order of increasing embryo diameter and developmental stage as outlined in Fig. 3. Data were602
normalized against the 3 best reference genes (SRP14, RPL4 and PGK1) and plotted as the 603
mean and range (error bars) of technical duplicates. The embryo with the lowest expression 604
for each gene was taken as the reference to calculate relative amounts for all embryos.605
606
Fig. 6. Normalized gene expression in equine embryos grouped by developmental stage.607
Stages arranged in order of advancing development. Data were normalized against the 3 best 608
reference genes (SRP14, RPL4 and PGK1) and plotted as mean ±SEM of biological 609
replicates. The developmental stage with the lowest expression for each gene was taken as the 610
reference to calculate relative amounts for all stages. Values not sharing the same letter differ 611
significantly (P≤0.05).612
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Tables613
Table 1. Primer details for candidate reference genes used in quantitative PCR614
Symbol Gene name
GenBank 
accession 
number
Primer location Sequence Product size (bp)* TA (°C) Cq range
ACT† actin (β, γ1, hypothetical product)
NM_001081838
XM_001488883
XM_001487824
exon 2–3
exon 1–2
exon 1
forward 5’-GGCACCACACCTTCTACAAC-3’
reverse 5’-CGACATAGCAGAGCTTCTCC-3’
402 (850)
402 (680)
402 (402)
67.0–57.0‡ not applicable
PGK1 phosphoglycerate kinase 1 XM_001502668 exon 9–10/11 forward 5’-CAAGAAGTATGCTGAGGCTG-3’reverse 5’-AGGACTTTACCTTCCAGGAG-3’ 260 57.0 20.6–34.8
SRP14 signal recognition particle 14kDa XM_001503583 exon 2/3–3 forward 5’-CTGAAGAAGTATGACGGTCG-3’reverse 5’-CCATCAGTAGCTCTCAACAG-3’ 100 55.0 23.6–37.1
RPL4 ribosomal protein L4 XM_001497094 exon 6/7–8 forward 5’-CATCCCTGGAATTACTCTGC-3’reverse 5’-CGGCTAAGGTCTGTATTGAG-3’ 203 61.5 18.3–31.9
RPL13A ribosomal protein L13A XM_001491876 exon 6/7–8 forward 5’-CTACACGAAAGTTTGCCTACC-3’reverse 5’-TTGAGGACCTCTGTGTATCTG-3’ 198 61.5 19.9–34.3
CDX2 caudal type homeobox 2 XM_001915508 exon 3–4 forward 5’-CAGTCGGTACATCACCATCC-3’reverse 5’-GCTGCTGCTGCAACTTCTTC-3’ 136 61.4 17.9–33.0
† used to check quality and gDNA contamination of cDNA only615
* numbers in parentheses represent gDNA amplicons616
‡ touchdown protocol decreasing from 67 to 57 °C (1 °C per cycle over the first 10 cycles)617
618
619
Table 2. Ranking of reference genes by gene expression stability measure (M)620
Gene (M value)
Ranking†
All genes included Minus RPL4 Minus RPL13A
1 RPL4 (0.463) SRP14 (0.567) SRP14 (0.497)
2 SRP14 (0.508) PGK1 (0.631) RPL4 (0.528)
3 RPL13A (0.566) RPL13A (0.666) PGK1 (0.606)
4 PGK1 (0.596) CDX2 (0.809) CDX2 (0.766)
5 CDX2 (0.797) - -
† less stably expressed genes have higher M values621
bold=gene negatively affected by exclusion622
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100
150
200
250
300
350
RPL13A 1.0 1.3 1.6 0.8 0.8 1.3 4.1 3.2 2.0 2.8 5.1 7.6 9.9 16.2 13.2 8.4 31.3 22.8 31.5 117.4 79.0
RPL4 1.0 1.3 1.7 0.9 1.0 1.6 3.9 3.6 2.7 3.9 4.8 8.1 14.4 17.0 21.3 9.3 40.0 34.1 41.6 187.3 137.2
PGK1 1.0 3.2 2.5 1.0 0.9 2.0 4.4 4.0 6.2 7.9 11.7 11.1 14.2 40.3 41.3 10.5 54.0 49.3 93.9 367.5 175.8
SRP14 1.0 1.9 2.0 1.1 0.8 2.1 4.2 4.0 4.5 6.0 5.7 13.7 23.1 19.2 41.1 14.4 59.3 53.6 67.7 325.5 265.2
CDX2 1.0 1.0 2.7 0.3 1.3 2.3 5.6 7.1 4.4 5.4 8.4 21.1 32.1 29.9 52.1 27.8 79.1 73.5 124.2 332.0 274.6
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